0 CHECKOUT

Sydkraft and Vattenfall Ratings Affirmed;Outlook on Sydkraft Stable, Outlook on Vattenfall Neg Dec 99

  • ID: 2027238
  • December 1999
  • Standard & Poors

FEATURED COMPANIES

  • E.ON Sverige AB
  • Vattenfall AB
  • Vattenfall Treasury AB
  • Vattenfall Treasury Inc.
  • MORE

Abstract
LONDON (Standard & Poor's CreditWire) Dec. 1, 1999--Standard & Poor's today affirmed its ratings on the Swedish electric utilities Sydkraft AB, and Vattenfall AB and related entities. The outlook on Sydkraft is stable and the outlook on Vattenfall is negative. (See list below for all ratings.) The affirmations follow the Nov. 30, 1999, announcement of a voluntary compensation settlement between the Swedish government and Sydkraft, regarding the state's decision to close Sydkraft's nuclear reactor Barsebäck unit 1 (B1), which also involves 100% state-owned Vattenfall. Standard & Poor's believes that the outcome is relatively credit neutral for both companies. According to the settlement, Vattenfall will provide Sydkraft with nuclear capacity from Vattenfall's Ringhals plant equivalent to that produced by B1. Vattenfall...

Companies mentioned in this report are:
- E.ON Sverige AB
- Vattenfall AB
- Vattenfall Treasury AB
- Vattenfall Treasury Inc.

Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns READ MORE >

Note: Product cover images may vary from those shown

- E.ON Sverige AB
- Vattenfall AB
- Vattenfall Treasury AB
- Vattenfall Treasury Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: This Credit Rating Report will be emailed to you.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.